Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Rv2608 encodes the M. tuberculosis PPE41 protein—a member of the immunomodulatory PE/PPE family—recognized for its diagnostic value due to strong humoral immunogenicity. While not highly sensitive on its own as a biomarker, truncation or combination with other antigens enhances detection rates across diverse patient groups. Its stable genetic profile and capacity for inducing protective immunity make it an attractive candidate both for improved diagnostics and inclusion in multi-component vaccine strategies against TB.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycobacterium tuberculosis Antigen Rv2608 (Rv2608).